Investor Presentaiton

Targeted Protein Degradation offers the promise of novel targets and clinical differentiation for existing targets Expanded universe of targets (e.g., scaffolding proteins, transcription factors) Potentially superior efficacy (e.g., overcome resistance, higher selectivity) Drugged: Target with approved drugs (3%) "Dark 659 Genome": No known (3%) 1,607 (8%) 6,007 disease (30%) association (30%) Human protein - Coding genes -20,000 Ill Bristol Myers Squibb™ Druggable: No approved drugs, but bind small molecules with high potency (8%) Disease- relevant: No known potent binders, but implicated in 12,139 (61%) disease (61%) Scaffold Scaffold protein Small molecule enzyme inhibitor Transcription factor CELMOD Kinase Inhibitors Not for Product Promotional Use 32

View entire presentation